Clinical Effect of Combination Therapy of Milrinone and Nifedipine in Treating Chronic Pulmonary Heart Disease

Abstract

Objective: To analyze the therapeutic effect achieved and the occurrence of adverse reactions in patients with chronic pulmonary heart disease treated with milrinone combined with nifedipine. Methods: 120 cases of chronic pulmonary heart disease patients treated in the hospital from May 2023 to February 2024 were selected as research subjects, and based on the randomized numerical table method, the 120 patients were divided into the study group and the comparison group, and the treatment of milrinone combined with nifedipine was carried out for 60 patients in the study group, and the conventional treatment was carried out for 60 patients in the comparison group, so as to make a comparison on the therapeutic effect and the occurrence of adverse reactions of patients in the two groups. The therapeutic effects and adverse reactions of the two groups were compared. Results: After receiving medication of milrinone combined with nifedipine, the patients in the study group had an exertional lung capacity of 68.12 ± 5.63% and a maximal expiratory volume of 82.41 ± 7.84 L/min, which were significantly higher than those in the comparison group, and the total rate of adverse reactions of the patients in the study group was 1.67%, which was significantly lower than that of the comparison group, with a P value of < 0.05, which is statistically significant. Conclusion: In the implementation of treatment for patients with chronic pulmonary heart disease, the treatment of milrinone combined with nifedipine can significantly improve the patient’s exertional lung capacity and maximum expiratory volume, and the chance of adverse reactions in patients will also be significantly reduced.